ASignal is a systematic stock analysis platform that evaluates every stock through three independent investment frameworks - Buffett (value), Ackman (activist), and Dalio (macro) - with an adversarial challenger review and algorithmic confidence scoring. It produces the ASignal Rank (1-4) for each analyzed stock.

How does ASignal Rank work?

ASignal Rank is a 1-4 scoring system: 1 = Strongest data alignment, 2 = Positive alignment, 3 = Neutral, 4 = Negative alignment. These represent how strongly our analytical frameworks agree on the direction of publicly available data. It is computed by 10+ analysis agents evaluating technical indicators, fundamentals, sentiment, and three investor frameworks, then stress-tested by an adversarial challenger agent.

How much does ASignal cost?

ASignal offers a free tier. The Signal plan costs $19/month or $180/year ($15/month equivalent, 21% discount). The free tier includes 24-hour full access on signup, then top-15 daily research summaries on a 7-day delay, while paid subscribers get real-time access.

What stocks does ASignal analyze?

ASignal analyzes S&P 500 stocks daily plus trending stocks discovered from Reddit, market movers, financial news, and social media. Each stock runs through a 5-phase pipeline: data collection, analysis, multi-strategist evaluation, adversarial review, and final decision.

Is ASignal better than Seeking Alpha or TipRanks?

ASignal uses a multi-framework analysis pipeline with 10+ specialized agents including an adversarial challenger, while Seeking Alpha relies on human analysts and TipRanks aggregates Wall Street consensus. ASignal is priced at $19/month versus Seeking Alpha at $25/month and TipRanks at $30/month, and provides transparent reasoning for every signal.

Is ASignal financial advice?

No. ASignal is not a registered investment advisor, broker-dealer, or financial planner. ASignal is a data research tool that aggregates publicly available financial data for informational and educational purposes only. All scores, analyses, and reports reflect algorithmic output - not personalized investment recommendations. Always do your own research and consult a licensed financial professional before making investment decisions.

Ultragenyx Pharmaceutical Inc.RARE

Healthcarediscovered

Neutral

ASignal's systematic analysis rates RARE as Neutral. Ultragenyx Pharmaceutical Inc. has a market cap of $3.53B, a -90.9% net margin, and -2.2% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 8, 2026

The case on RARE

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case

MACD above signal line with expanding histogram, confirming bullish trend
Price trading above 20-day and 50-day moving averages, indicating uptrend
Positive price momentum and current price near upper Bollinger Band, suggesting strength

Bear case

Extremely negative profitability metrics including -90.9% net margin and -102.2% operating margin
Negative free cash flow of $-219M and negative operating cash flow of $-497M
Negative price-to-book ratio (-14.90x) indicating balance sheet concerns or negative equity
Revenue growth declining YoY at -2.2%
EV/EBITDA of -8.68x suggests unprofitable operations
Lack of Reddit mentions may indicate low retail investor interest

Key facts

Sector

Healthcare

Market cap

$3.53B

Gross margin

-28.1%

Net margin

-90.9%

Rev growth YoY

-2.2%

Price (Jul 8, 2026)

$35.87

Subscriber-only

See the full verdict on RARE

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

Open full analysis →Pricing

How ASignal analyzes RARE

Most investors never get a second opinion, let alone several. ASignal runs RARE past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.